Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Tokushima University has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This indicates that the university's current patent applications are being evaluated by different technical groups within the USPTO. The dispersion across 2 distinct art units suggests that the subject matter of these applications is diverse enough to require different specialized reviews despite both falling under the same technology area.
REGA, KYLE THOMAS is the busiest examiner for this portfolio, with 1 pending office action. This examiner handles half of the university's current pending actions. Since there are 2 distinct examiners for 2 pending actions, each examiner is responsible for exactly one matter. This arrangement means the university is currently navigating two separate examination tracks, which may result in different timelines and outcomes for each pending action. Practitioners should be prepared for non-uniform prosecution experiences across these two distinct units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGA, KYLE THOMAS | 1 | 62.7% | +41.4% |
| HELM, CARALYNNE E | 1 | 28.9% | +49.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17620192 | DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION | HELM, CARALYNNE E | 140d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17620192 | DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION | HELM, CARALYNNE E | 140d overdue |
| 18030704 | TECHNIQUE FOR MODIFYING TARGET NUCLEOTIDE SEQUENCE USING CRISPR-TYPE I-D SYSTEM | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030704 | TECHNIQUE FOR MODIFYING TARGET NUCLEOTIDE SEQUENCE USING CRISPR-TYPE I-D SYSTEM | REGA, KYLE THOMAS | 1636 | §103§112DP | Final Rejection | — | Pending | Apr 06, 2023 |
| 17620192 | DRUG DELIVERY COMPOSITION AND PHARMACEUTICAL COMPOSITION | HELM, CARALYNNE E | 1615 | §103 | Final Rejection | 140d overdue | Pending | Dec 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial